| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW |
The Royal Veterinary and Agricultural University, Department of Veterinary Pathobiology, Ridebanevej 9, DK-1870 Frederiksberg C, Denmark
1 Hvidovre Hospital, Department of Surgical Gastroenterology, DK-2650 Hvidovre, Denmark
2 Rigshospitalet, Department of Oncology, Blegdamsvej 9, DK-2100 Copenhagen, Denmark
(Requests for offprints should be addressed to SO Wurtz; Email: suw{at}kvl.dk)
 |
Abstract |
|---|
 Top Abstract IntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
Whether patients diagnosed with primary breast cancer are offered adjuvant systemic treatment in addition to loco-regional therapy of the tumor is determined by a number of prognostic variables such as nodal status, tumor size, grade of malignancy, age and hormone receptor status, with nodal status being the most important (Danish Breast Cancer Cooperative Group Guidelines 2004, www.dbcg.dk; Goldhirsch et al. 2003). Using these prognostic variables, adjuvant systemic therapy is offered to the majority of node-negative patients (~60%) and to all node-positive patients, i.e. to a prognostically heterogenous group with risks ranking from 10 to 80%. With the adjuvant systemic therapy approximately 30–40% of the expected deaths can be avoided (Early Breast Cancer Trialists’ Collaborative Group 1998a, 1998b); however, in absolute terms the mortality reduction ranks from only a few percent in the lower-risk group and up to 25% in the higher-risk group. Thus, although adjuvant systemic therapy has led to a significant improvement in the survival in the breast cancer population a large proportion of the patients are over-treated. Since the treatment causes several adverse side effects and inflicts considerable costs on the society, additional prognostic factors need to be identified in order to improve risk classification and thereby a more rational management of breast cancer patients.
Several promising prognostic markers are emerging and currently under investigation. Besides a brief description of some of the most important of these, this review will be focused on tissue inhibitor of metallo-proteinases-1 (TIMP-1), which has recently been discovered to carry valuable prognostic information in primary breast cancer.
|
Emerging candidates for new prognostic factors in breast cancer |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
Tumor invasion and metastasis are the primary determinant of patient outcome and concordantly molecules involved in these processes are obvious candidates for new prognostic markers in breast cancer. Proteolytic enzyme systems are responsible for the turnover of the extracellular matrix (ECM) in normal physiological conditions such as embryo development, morphogenesis and tissue remodelling (i.e. wound healing). In addition, it is well established that deregulation of these enzyme systems is associated with the malignant progression of cancer cells. It is believed that overexpression of proteolytic enzymes in the tumors render the cells capable of breaking down the ECM and basement membrane (BM), which under normal conditions maintain the integrity of the tissues, thereby allowing cells to invade the surroundings. In this regard, the uPA system, which is known to play a crucial role in cancer metastasis, has gained much attention (Andreasen et al. 1997). Numerous groups have independently shown that high levels of uPA and, paradoxically, high concentrations of its inhibitor PAI-1 correlate with poor prognosis in breast cancer (reviewed in Schmitt et al. 1997). The surprising finding concerning PAI-1 has recently been partly explained by the demonstration of an anti-apoptotic (Kwaan et al. 2000) as well as a pro-angiogenic (Bajou et al. 1998) effect of this protein. In fact, uPA and PAI-1 are among the first prognostic indicators to have their clinical value confirmed in evidence-level 1 studies (Hayes et al. 1996), and they are now considered for the routine assessment of prognosis in patients with primary breast cancer (Jänicke et al. 2001, Duffy 2002, Look et al. 2002). By using uPA and PAI-1 in stratification of node-negative breast cancer patients approximately 50% of these patients can be considered at low risk of experiencing recurrence of disease and accordingly may be spared the toxicity of adjuvant systemic therapy (Jänicke et al. 2001). Thus, using uPA and PAI-1 in prognostic stratification an improvement is achieved although complete separation of high- and low-risk node-negative women is still not possible. To this end additional prognostic factors are needed.
Other proteolytic enzymes known to play a pivotal role in cancer dissemination are the matrix metalloproteinases (MMPs). MMPs are a family of zinc-dependent endopeptidases, which together are able to cleave virtually every component of the ECM including BM (reviewed in Stamenkovic 2000, Egeblad & Werb 2002). The expression and activation of MMPs are increased in almost all human cancers compared with normal tissues and this increase has been associated with a poor patient prognosis (Chenard et al. 1998, Nakopoulou et al. 2002b, Ranuncolo et al. 2003, Talvensaari-Mattila et al. 2003, Leppä et al. 2004). In addition to the MMPs, one of the four natural inhibitors of the MMPs, tissue inhibitor of metalloproteinases type-1 (TIMP-1), has also been shown to be upregulated in numerous cancers including breast cancer and surprisingly, as was the case for PAI-1, this upregulation has in several cases been shown to be associated with a poor patient prognosis (Ree et al. 1997, McCarthy et al. 1999, Nakopoulou et al. 2002a, Schrohl et al. 2003, 2004). The upregulation of TIMP-1 in cancer together with the association to a poor prognosis could reflect the fact that the balance between expression of MMPs and TIMP-1, although still favouring MMPs, is at a higher overall level than in non-cancerous conditions. High TIMP-1 levels would therefore be associated with a worse prognosis but would not be the cause of it (Egeblad & Werb 2002). However, several lines of evidence have recently implied that TIMP-1 is a multifunctional protein that in addition to its MMP-inhibitory effect also possesses distinct tumor-stimulatory functions. Indication of a prognostic significance of TIMP-1 has resulted in extensive investigation of this new putative prognostic marker in breast cancer. In the following sections the proposed cancer-related functions of TIMP-1 will be outlined.
|
TIMP-1 |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
High levels of TIMP-1 mRNA as well as TIMP-1 protein have been demonstrated in several types of cancer, including breast cancer, and this has been associated with a poor prognosis of the patients (Ree et al. 1997, McCarthy et al. 1999, Nakopoulou et al. 2002a, Schrohl et al. 2003, 2004). As for PAI-1, this paradox points to TIMP-1 as a multifunctional protein, which in addition to the MMP-inhibitory effect has distinct tumor-promoting functions. Proposed functions include growth promotion and anti-apoptotic effects as well as both anti- and pro-angiogenic functions, as will be described in the following sections.
|
TIMP-1 functions |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
Endogenous inhibitors such as TIMP-1 tightly control MMP activity. TIMP-1 binds non-covalently in a 1 : 1 stoichiometric fashion to the active form of MMPs thereby inhibiting the proteolytic activity of these enzymes. In addition, TIMP-1 can form complexes with pro-MMP-9 (Duffy et al. 2000). In spite of the fact that the interaction between TIMP-1 and MMPs is non-covalent the complex has proved to be rather stable (Welgus et al. 1985, Murphy et al. 1991). Mutational studies have shown that the N-terminal domain of TIMP-1 is critical for the inhibitory action. In a study conducted by Murphy and co-workers (1991) it was demonstrated that a truncated version of TIMP-1 containing only the N-terminal part of the protein retained the ability to inhibit MMPs as effectively as wild-type protein. The importance of the N-terminal domain of TIMP-1 in MMP inhibition is supported by the fact that point mutations introduced in this region of the protein abolish the MMP-inhibitory capacity (Chesler et al. 1995). Multiple sites in the N-terminal domain are probably involved in the interaction with MMPs. For instance, residues around the disulfide bond Cys-1–Cys-70 have been demonstrated to be crucial for the inhibitory activity of TIMP-1 (Caterina et al. 1997).
The mechanisms of MMP inhibition by TIMP-1 have been the subject of excessive investigations. In 1997, the first structure of complete TIMP-1 in complex with the catalytic domain of human MMP-3 was published (Gomis-Rüth et al. 1997). Subsequently the X-ray structure of TIMP-2 in complex with membrane type 1 MMP has been described (Fernandez-Catalan et al. 1998). These publications have revealed several features concerning the interaction between TIMPs and the MMPs. TIMP-1 has the shape of an elongated wedge and MMPs contain a small active-site cleft, which harbours the catalytic zinc atom (Maskos & Bode 2003). In complex with MMPs, the edge of the TIMP-1 molecule binds and occupies the entire length of the active-site cleft of MMPs (Gomis-Rüth et al. 1997, Fernandez-Catalan et al. 1998). In addition, the structural studies have supported the previous observation that TIMP-1 interacts with MMPs predominantly through its N-terminal moiety. Furthermore, these studies have identified segments of the TIMP-1 protein participating in the interaction with MMPs as well as residues crucial for inhibition. For example, the central disulfide-link segments around Cys-1–Cys-70 have been shown to be important docking sites of TIMP-1 and the residue Cys-1 has been implicated in the chelating of the catalytic zinc ion in MMPs, thereby playing an important part in the inhibitory function of TIMP-1 (Gomis-Rüth et al. 1997).
TIMP-1 and stimulation of proliferation
TIMP-1 was originally purified as a protein possessing erythroid-potentiating activity, thus stimulating the proliferation of early erythroid precursor cells and the growth of the K-562 human erythroleukemia cell line (Westbrook et al. 1984, Avalos et al. 1988). The identity of this protein as TIMP-1 was later established (Docherty et al. 1985). Subsequently the cell-growth-promoting effects of TIMP-1 has been extended to a wide range of normal cell types as well as neoplastic cell types (Bertaux et al. 1991, Hayakawa et al. 1992).
The molecular basis of growth control by TIMP-1 remains to be fully elucidated. However, several models have been proposed concerning the mechanisms by which TIMP-1 mediates growth promotion. These will be discussed below.
Several lines of evidence indicate that TIMP-1-mediated stimulation of cell proliferation is independent of its MMP-inhibitory effect. In support of this view are findings demonstrating that the two major activities of TIMP-1, i.e. inhibition of MMPs and stimulation of growth, are functionally distinct as well as possibly structurally separate. Chesler et al.(1995) showed that a mutated form of TIMP-1 lacking regions necessary for MMP inhibition was capable of stimulating the growth of erythroid precursors as effectively as non-mutated TIMP-1. Furthermore, it has been demonstrated that reduction/alkylation of TIMP-1, which eliminates the proteinase-inhibitory activity (Hayakawa et al. 1994), does not affect the growth promoting effect of TIMP-1 (O’Shea et al. 1992). These results indicate that the influence of TIMP-1 on the growth of these cells is independent of its ability to inhibit MMPs and that stimulation of growth and MMP inhibition are structurally distinct activities of the protein. In addition to the findings mentioned above, binding sites specific for TIMP-1 have been identified on the surface of several human cell types responding to this protein including keratinocytes, erythroid precursors, breast carcinoma cells and K-562 cells (Avalos et al. 1988, Bertaux et al. 1991, Luparello et al. 1999, Ritter et al. 1999).
These observations have lead to the currently prevailing view that TIMP-1 stimulates cell proliferation through a direct interaction with an as-yet unidentified cell-surface receptor involving no mediation by the MMP system. Binding of TIMP-1 to this receptor would then in turn initiate an intracellular signalling cascade resulting in a cellular response of proliferation. In support of such a mechanism, Luparello and co-workers (1999) investigated the proliferative effect of TIMP-1 on two different breast carcinoma cell lines, BC-3A and BC-61, endowed with different malignant potential. Data from this study indicate that only the more tumorigenic cell line (BC-61) was responsive to TIMP-1 treatment by increasing its proliferative rate in a dose-dependent manner (Luparello et al. 1999). The same authors explained this phenomenon by the identification of TIMP-1-binding proteins uniquely present on BC-61 cells. These TIMP-1-binding proteins were shown not to possess any gelatinolytic activity and therefore they did not represent membrane-associated MMPs. These findings support the hypothesis of an actual receptor-mediated action of TIMP-1. Moreover, the study implies that heterogeneity of the response to TIMP-1 could be expected for cells with differential expression of this receptor, i.e. TIMP-1 may preferentially bind to neoplastic cells selectively expressing TIMP-1 receptors. Thus, the appearance or upregulation of a TIMP-1 receptor could be associated with the degree of malignancy.
The identification of the intracellular signalling pathway initiated by TIMP-1 upon binding to the putative membrane receptor has been the emphasis of numerous studies. However, controversy still exists as to how TIMP-1 transduces its growth signal into the cell. For example, binding of a fusion protein of human TIMP-1 and enhanced green fluorescent protein to the surface of MCF-7 breast carcinoma cells has been demonstrated to result in enhanced proliferation of these cells (Ritter et al. 1999). Interestingly, this binding was followed by translocation of TIMP-1 to the nucleus. These results raise the possibility that following binding to the cell surface TIMP-1 translocates to the nucleus and in turn directly affects replication and/or transcription leading to cell proliferation. Likewise, accumulation of TIMP-1 has also been shown in the nuclei of human gingival fibroblasts, reaching a maximum in the S-phase of the cell cycle (Zhao et al. 1998).
An alternative mechanism of action is that TIMP-1 binds to the cell surface and initiates a signal transduction cascade mediating the growth signal into the cell. Thus, it has been found that following binding of TIMP-1 to the cell surface an increase in tyrosine-specific phosphorylation of cellular proteins, which is a widely recognized intracellular signal used by several growth factors, was induced (Luparello et al. 1999). Likewise, a TIMP-1-mediated increase in tyrosine-targeted phosphorylation resulting in growth promotion of osteosarcoma cells have been demonstrated (Yamashita et al. 1996). These studies suggest a crucial role for tyrosine kinases in the signal transduction of TIMP-1. Furthermore, demonstration of the activation of one of the known mitogen-activated protein (MAP) kinases, extracellular-signal-regulated kinase 2 (ERK2), following treatment with TIMP-1 suggests that a MAP kinase signalling pathway could be implicated in TIMP-1-dependent growth signalling (Yamashita et al. 1996). The recent finding that TIMP-1 is able to activate Ras (stimulate the complex formation between Ras and GTP) as well as to enhance the binding between Ras-GTP and Raf-1 has extended the model (Wang et al. 2002). The fact that Ras is a well-established activator of the MAP kinase cascade supports the hypothesis that the proliferative effect of TIMP-1, as for several other known growth factors, is mediated by tyrosine-specific phosphorylation through the MAP kinase pathway.
Whether TIMP-1 enters the cell and directly influences the nucleus or whether TIMP-1 merely stays outside the cell and initiates a signalling cascade thereby indirectly transmitting the growth signal to the nucleus remains to be elucidated.
An alternative model suggests that the apparent proliferative action of TIMP-1 is dependent on its ability to inhibit MMPs, rather than to stimulate a cell-surface receptor by a process independent of its MMP-inhibitory effect; that is, an indirect action. In this regard, it has been demonstrated that TIMP-1 and the synthetic inhibitor of MMPs, GM6001, stimulated proliferation of the cancer cell line MDA-MB-435 with similar kinetics, indicating that the two inhibitors stimulate proliferation using the same mechanisms (Porter et al. 2004). Furthermore, a GM6001 derivative incapable of inhibiting MMPs had no effect on proliferation, confirming that the growth-stimulatory function of GM6001 was dependent on its ability to inhibit MMPs. By employing several specific signal transduction inhibitors the researchers showed that stimulation of growth by TIMP-1 occurred through the MAP kinase/ERK kinase (MEK)/ERK and p38 kinase pathways. The authors proposed mechanisms by which TIMP-1 mediated MMP inhibition could stimulate growth. One of these putative mechanisms involved the possibility that TIMP-1 prevents the degradation of a newly synthesized growth factor by constitutively active MMPs thereby allowing the growth factor to stimulate the cells. Although indicative, results from this study do not provide conclusive evidence that TIMP-1 stimulates cell growth through the inhibition of MMPs. It cannot be excluded that the synthetic MMP inhibitor tested and TIMP-1, although seemingly similar, work through different mechanisms. The idea of the existence of a TIMP-1 receptor can therefore not be abandoned based on this study alone and finally, it should be emphasized that the two overall models (direct or indirect mechanisms of TIMP-1) are not mutually exclusive.
From the above discussion it is evident that further studies are necessary in order to fully uncover the mechanisms by which TIMP-1 stimulates proliferation.
|
TIMP-1 and inhibition of apoptosis |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
The first mechanism suggested for TIMP-1 is dependent on its ability to inhibit the activity of MMPs. In this regard, an anti-apoptotic effect of TIMP-1 has been demonstrated on human and rat hepatic stellate cells. This effect was shown to be dependent on the MMP inhibitory function of TIMP-1 since a mutated form of this protein possessing no MMP-inhibitory capacity was not able to exert the anti-apoptotic effect (Murphy et al. 2002). So how does TIMP-1 suppress apoptosis by inhibiting MMPs? Studies have shown that integrity of the ECM and BMs as well as cell–matrix interactions suppress apoptosis and maintain the differentiated state of anchorage-dependent mammalian cells. In addition, disruption of these cells from their association with the matrix by MMP-mediated degradation of the ECM results in induction of molecular effectors of apoptosis such as the cas-pases. This leads to loss of the differentiated state and apoptotic cell death both in culture and in vivo (Boudreau et al. 1995). This shows that an intact matrix plays a key role in regulation of apoptosis, probably by providing a direct cell survival signal or by preventing the release of matrix-bound pro-apoptotic factors. Induction of apoptosis may then occur as a consequence of proteolytic activity of MMPs, removing this cell survival signal and/or liberating/activating pro-apoptotic factors from the matrix. Keeping this in mind it is obvious to speculate that TIMP-1 inhibition of apoptosis may result from its ability to preserve integrity of the ECM and stabilize cell–ECM interactions through inhibition of MMPs. In support of this model, Alexander et al.(1996) demonstrated that mammary epithelial cells derived from mice over-expressing MMP-3 underwent excessive apoptosis. When these mice were crossed with mice overexpressing TIMP-1, apoptosis was significantly reduced (Alexander et al. 1996).
TIMP-1 may also exert its anti-apoptotic effect independently of its ability to inhibit MMPs. In a study conducted by Guedez et al.(1998) it was found that the level of TIMP-1 expression was positively correlated with resistance to apoptosis in Burkitt’s lymphoma cells and that TIMP-1 inhibited apoptosis in normal tonsillar B cells. This anti-apoptotic effect of TIMP-1 was not a result of inhibition of MMPs as reduced/alkylated TIMP-1 completely devoid of MMP inhibitory activity was still able to suppress apoptosis. In addition, TIMP-1 overexpression inhibits apoptosis even after the loss of cell adhesion in human breast epithelial MCF10A cells, suggesting that the anti-apoptotic effect of TIMP-1 does not depend on its ability to stabilize cell–matrix interactions (Li et al. 1999). The mechanism for this MMP independent anti-apoptotic effect is not understood at present but as was the case concerning the proliferative effect of TIMP-1 it has been speculated that inhibition of apoptosis occurs via binding of TIMP-1 to a cell-surface receptor. Cell-surface binding of TIMP-1 has indeed been demonstrated for cell types responding to the anti-apoptotic activity of this protein (Guedez et al. 1998). Thus, TIMP-1 may exert its anti-apoptotic effect by targeting unidentified TIMP-1-binding proteins on the cell surface, thereby initiating as-yet undefined signalling pathways. Suggestions have been made regarding the signalling pathways possibly regulated by TIMP-1. In the MCF10A breast epithelial cell line overexpression of TIMP-1 was shown to induce constitutive activation of focal adhesion kinase (FAK) through tyrosine phosphorylation (Li et al. 1999, Liu et al. 2003). FAK has previously been shown to be upstream regulator of the phosphatidylinositol-3 kinase (PI-3 kinase), leading to regulation of the Bcl-2 family members, a well-characterized signalling pathway leading to cell survival. Phophorylated FAK associates with and thereby activates the PI-3 kinase, which then in turn activates the Akt kinase. Akt phosphorylates the protein Bad, which as a result is sequestered in the cytoplasm by the capture protein 14-3-3 and can therefore no longer interact with and inhibit Bcl-2 and Bcl-XL. Bcl-2 and Bcl-XL are proteins situated in the mitochondria membrane and when activated these anti-apoptotic proteins inhibit Bax, thereby preventing the release of cytochrome c from the mitochondria. This in turn prevents activation of the caspase cascade and accordingly prevents apoptosis. Thus TIMP-1 may inhibit apoptosis by acting like a trophic factor initiating the survival pathway including FAK, PI-3 kinase, Akt and Bcl-2 family members resulting in inhibition of caspase activation and thereby inhibition of apoptosis (Fig. 1
).
|
|
TIMP-1 and angiogenesis |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
Firstly, TIMP-1 has been shown to inhibit angiogenesis. For example, bovine aortic endothelial cells overexpressing TIMP-1 display a significant reduction in migration through gelatin-coated membranes (a model-system representing the ECM and BM) compared with control cells (Fernandez et al. 1999). Since this reduction was seen only when gelatin-coated membranes and not uncoated membranes were used, it was speculated that TIMP-1-mediated inhibition of endothelial cell migration was dependent on the anti-proteolytic activities of this inhibitor. During angiogenesis endothelial cells locally degrade the vascular basal lamina and migrate into the ECM to form new capillaries (Ausprunk & Folkman 1977). This is accomplished using proteinases including MMPs. Realising the importance of proteolytic activity in new vessel formation the antiangiogenic effect of TIMP-1 should come as no surprise. Another possibility is that by inhibiting MMPs TIMP-1 prevents the angiogenic switch. MMP-9 has been shown to be able to convert normal non-angiogenic endothelial cells of pancreatic islets into highly angiogenic cells (i.e. the angiogenic switch; Bergers et al. 2000). This was shown to be a result of MMP-9-mediated mobilization of VEGF from the ECM, rendering VEGF more available to the endothelial cells. Furthermore, when exposing the endothelial cells to a synthetic MMP-9 inhibitor, the angiogenic potential of the cells was significantly reduced. Thus, it seems logical that the suppression of MMP activity by TIMP-1 may inhibit angiogenesis by preventing mobilization of VEGF.
Secondly, a stimulatory role of TIMP-1 in the process of angiogenesis has been proposed. Some MMPs play a critical role in generation of potent inhibitors of angiogenesis. For example, MMP-12 is most efficient in converting plasminogen into angiostatin, which is a well-known antiangiogenic factor (Cornelius et al. 1998). In addition, the generation of endostatin, another inhibitor of angiogenesis, has been shown to be mediated by MMPs, which cleave and thereby release endostatin from the precursor molecule collagen (Wen et al. 1999). Therefore, by inhibiting these MMPs TIMP-1 may prevent angiostatin and endostatin production, thus playing a positive role in tumor angiogenesis. In this regard, it has been shown that tumors derived from rat breast carcinoma cells overexpressing TIMP-1 grew larger and became more vascularized compared with controls (Yoshiji et al. 1998). In addition, overexpression of TIMP-1 by the rat carcinoma cells was associated with a marked upregulation of VEGF expression, explaining the growth advantage for cells possessing high levels of TIMP-1. A close relationship between TIMP-1 and VEGF expression was also found in clones of human MCF-7 breast carcinoma cells lines. These findings indicate that by stimulating the expression of VEGF directly, TIMP-1 confers growth advantage on tumors overexpressing this inhibitor by promoting angiogenesis, thereby promoting vascularization of the tumor. The mechanisms involved in the induction of VEGF expression by TIMP-1 are not known at present. However, since, as mentioned previously, TIMP-1 has been found to accumulate in the nucleus (Zhao et al. 1998, Ritter et al. 1999) it is reasonable to speculate that TIMP-1 can influence transcriptional activation directly.
|
Expression and localization of TIMP-1 in breast cancer tissue |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
Taken together, these studies demonstrate that the expression of TIMP-1 mRNA is upregulated in breast cancer tissue compared with benign or normal tissue. In addition, they indicate that this upregulation does not only apply to the mRNA levels but also to the protein levels of TIMP-1. Furthermore, the data show that stromal cells of the tumors rather than the cancer cells themselves are responsible for the production of TIMP-1.
|
Current status on TIMP-1 and prognosis in primary breast cancer |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
In a study conducted by Ree et al.(1997) the expression of TIMP-1 mRNA was assessed by Northern blotting in human primary breast carcinomas from 34 patients and TIMP-1 mRNA levels were correlated with known clinicopathological prognostic parameters and with clinical outcome. It was demonstrated that the presence of high levels of TIMP-1 mRNA were associated strongly with early death. In addition, the level of TIMP-1 mRNA correlated significantly with nodal status and development of distant metastases, whereas no correlation was found to other prognostic markers such as age, tumor size, grade of malignancy or hormone receptor status, suggesting that TIMP-1 can provide independent prognostic information. In situ hybridization studies have supported the independent prognostic value of TIMP-1 in breast cancer by semi-quantitative estimation of the expression of inhibitor mRNA levels (Nakopoulou et al. 2002a). In 117 invasive breast carcinomas high levels of TIMP-1 mRNA correlated significantly with the presence of lymph node metastases and short survival but not with other known prognostic indicators such as menopausal status, tumor size and grade of malignancy (Nakopoulou et al. 2002a).
Prognostic studies of total TIMP-1 protein levels have supported the association between high tumor-tissue TIMP-1 levels and a poor prognosis in breast cancer. McCarthy et al.(1999) assessed the levels of TIMP-1 protein by ELISA in cytosol extracts from 139 breast carcinomas, 15 fibroadenomas and 15 nodal metastases. The group found that the concentration of TIMP-1 was significantly higher in breast carcinoma and lymph node metastases compared with the benign fibroadenomas. Furthermore, it was demonstrated that patients with carcinomas containing high levels of TIMP-1 had shorter disease-free survival as well as shorter overall survival. Also by employing ELISA, Schrohl et al.(2003) investigated the level of TIMP-1 in 341 tumor tissue extracts from patients suffering from primary breast cancer. It was shown that high tumor tissue levels of TIMP-1 were significantly associated with shorter overall survival and shorter recurrence-free survival (Schrohl et al. 2003). In multivariate analysis including nodal status, tumor size, hormone receptor status and grade of malignancy as well as the strong prognostic factors uPA and PAI-1, TIMP-1 still significantly predicted prognosis (Schrohl et al. 2003). Survival curves based on the total TIMP-1 measurements from this study are shown in Fig. 2. It is evident that patients with the highest tumor levels of TIMP-1 have significantly shorter recurrence-free survival compared with patients with lower levels of TIMP-1.
|
All of the studies described above have dealt with the total level of TIMP-1 (uncomplexed TIMP-1 and TIMP-1–MMP complexes). Interestingly, it has recently been demonstrated that including measurements of the uncomplexed fraction of TIMP-1 significantly improved the prognostic stratification based on TIMP-1 measurements (Würtz et al. 2005). This study showed that a score including information on total TIMP-1 as well as uncomplexed TIMP-1, thereby reflecting the level of TIMP-1–MMP complexes in the tumor was a more precise estimate of prognosis compared with total TIMP-1 alone. This study thus raises the hypothesis that it is the tumor level of MMPs that determines prognosis rather than TIMP-1 itself.
|
Conclusions and future directions |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
So far, the prognostic evaluation of TIMP-1 in breast cancer has been based primarily on measurements in tumor-tissue extracts. As a result of more sensitive diagnostic methods and thus earlier detection of the disease, tumors of still smaller size are obtained from the patients and this makes it increasingly difficult to acquire access to frozen tumor samples. In addition, the use of tumor tissue for tumor-marker measurements can be criticized because of the heterogeneity of this material. Therefore, future studies should be aimed at determining the prognostic value of TIMP-1 levels measured in blood, which is a more preferable type of specimen compared with tumor tissue. Sample collection is easier and less invasive and the need for histological evaluation of the tissue to be analysed does not apply to blood samples. Furthermore, the problem of tissue heterogeneity would be encompassed, as blood is a more homogenous material. Maybe most importantly, the possibility of taking blood samples during follow up of patients after primary surgery allows sequential measurements of TIMP-1.
Preliminary data have indicated that plasma TIMP-1 levels may carry important clinical information in breast cancer (Holten-Andersen et al. 1999). However, it should also be mentioned that other data have failed to demonstrate a difference in the plasma TIMP-1 levels between primary breast cancer patients and healthy controls (Holten-Andersen et al. 2002). Future studies should be directed at validating the potential prognostic value of TIMP-1 measurements in plasma.
Finally, the discovery of TIMP-1 as a multifunctional protein possessing several tumor-stimulating functions as discussed above suggests that TIMP-1 could represent a novel target for anticancer treatment.
|
Acknowledgements |
|---|
|
Funding |
|---|
There is no conflict of interest that would prejudice impartiality or be a potential conflict of interest for the authors.
|
References |
|---|
|
TopAbstractIntroductionEmerging candidates for new...TIMP-1TIMP-1 functionsTIMP-1 and inhibition of...TIMP-1 and angiogenesisExpression and localization of...Current status on TIMP-1...Conclusions and future...References |
|---|
Andreasen PA, Kjøller L, Christensen L & Duffy MJ 1997 The urokinase-type plasminogen activator system in cancer metastasis: a review. International Journal of Cancer 72 1–22.
Ausprunk DH & Folkman J 1977 Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvascular Research 14 53.[CrossRef][ISI][Medline]
Avalos BR, Kaufman SE, Tomonaga M, Williams RE, Golde DW & Gasson JC 1988 K562 cells produce and respond to human erythroid-potentiating activity. Blood 71 1720–1725.
Bajou K, Noel A, Gerard RD, Masson V, Brünner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D & Foidart JM 1998 Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Medicine 4 923–928.[CrossRef][ISI][Medline]
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z & Hanahan D 2000 Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology 2 737–744.[CrossRef][ISI][Medline]
Bertaux B, Hornebeck W, Eisen AZ & Dubertret L 1991 Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. The Society for Investigative Dermatology 97 679–685.
Boudreau N, Sympson CJ, Werb Z & Bissell MJ 1995 Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267 891–893.
Brew K, Dinakarpandian D & Nagase H 2000 Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochimica et Biophysica Acta 1477 267–283.[CrossRef][Medline]
Brummer O, Athar S, Riethdorf L, Löning T & Herbst H 1999 Matrix-metalloproteinases 1,2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridisation study. Virchows Archiv 435 566–573.[CrossRef][ISI][Medline]
Caterina NCM, Windsor LJ, Yermovsky AE, Bodden MK, Taylor KB, Birkedal-Hansen H & Engler JA 1997 Replacement of conserved cysteines in human tissue inhibitor of metalloproteinases-1. Journal of Biological Chemistry 272 32141–32149.
Chenard MP, O’Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Belloco JP & Duffy MJ 1998 High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. International Journal of Cancer 69 448–451.[CrossRef]
Chesler L, Golde DW, Bersch N & Johnson MD 1995 Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 86 4506–4515.
Clavel C, Polette M, Doco M, Binninger I & Birembaut P 1992 Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bulletin du Cancer 79 261–270.[ISI][Medline]
Cleator S & Ashworth A 2004 Molecular profiling of breast cancer: clinical implications. British Journal of Cancer 90 1120–1124.[CrossRef][ISI][Medline]
Coradini D & Daidone MG 2004 Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology 16 49–55.[CrossRef]
Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA & Shapiro SD 1998 Matrix metalloproteinases generate angiostatin: effects on neovascularization. Journal of Immunology 161 6845–6852.
Docherty AJP, Lyons A, Smith BJ, Wright EM, Stephens PE & Harris TJR 1985 Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318 66–69.[CrossRef][Medline]
Duffy MJ 2002 Urokinase plasminogen activator and its inhibitor PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clinical Chemistry 48 1194–1197.
Duffy MJ, Maguire TM, Hill A, McDermott E & O’Higgins N 2000 Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Research 2 252–257.[CrossRef][ISI][Medline]
Early Breast Cancer Trialists’ Collaborative Group 1998a Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352 930–942.[CrossRef][ISI][Medline]
Early Breast Cancer Trialists’ Collaborative Group 1998b Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351 1451–1467.[CrossRef][ISI][Medline]
Egeblad M & Werb Z 2002 New functions of the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2 161–174.[ISI][Medline]
Fernandez HA, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R, Mignatti P & Galloway A 1999 Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. Journal of Surgical Research 82 156–162.
Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H & Maskos K 1998 Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO Journal 17 5238–5248.[CrossRef][ISI][Medline]
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B & Senn HJ 2003 Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer. Journal of Clinical Oncology 21 3357–3365.
Gomis-Rüth FX, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagese H, Brew K, Bourenkov GP, Bartunik H & Bode W 1997 Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389 77–81.[CrossRef][Medline]
Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A & Stetler-Stevenson M 1998 In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. Journal of Clinical Investigation 102 2002–2010.[ISI][Medline]
Hanahan D & Weinberg RA 2000 The hallmarks of cancer. Cell 100 57–70.[CrossRef][ISI][Medline]
Hayakawa T, Yamashita K, Tanzawa K, Uchijima E & Iwata K 1992 Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Letters 298 29–32.[CrossRef][ISI][Medline]
Hayakawa T, Yamashita K, Ohuchi E & Shinagawa A 1994 Cell growth acitivity of tissue inhibitor of metalloproteinases-2 (TIMP-2). Journal of Cell Science 107 2373–2379.[Abstract]
Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L et al. 1996 Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute 88 1456–1466.
Hayes DF, Isaacs C & Stearns V 2001 Prognostics factors in breast cancer: current and new predictors of metastasis. Journal of Mammary Gland Biology and Neoplasia 6 375–392.[CrossRef][ISI][Medline]
Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Høyer-Hansen G, Brünner N & Stephens RW 1999 Quantification of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. British Journal of Cancer 80 495–503.[CrossRef][ISI][Medline]
Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW, Jensen V, Nielsen OH, Sørensen S, Overgaard J, Lilja H, Harris A, Murphy G & Brünner N 2002 Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clinical Cancer Research 8 156–164.
Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CGJF, Selbmann HK, Graeff H & Schmitt M 2001 Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute 93 913–920.
Jones JL, Glynn P & Walker RA 1999 Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. Journal of Pathology 189 161–168.
Kwaan HC, Wang J, Svoboda K & Declerck PJ 2000 Plasminogen activator inhibitor 1 may promote tumor growth through inhibition of apoptosis. British Journal of Cancer 82 1702–1708.[CrossRef][ISI][Medline]
Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, Hornebeck W, Haye B & Petitfrere E 2003 Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochemical Journal 372 767–774.[CrossRef][ISI][Medline]
Lambert E, Dassé E, Haye B & Petitfrè re M 2004 TIMPs as multifacial proteins. Critical Reviews in Oncology/Hermatology 49 187–198.[CrossRef]
Lee SJ, Yoo HJ, Bae YS, Kim HJ & Lee ST 2003 TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochemical and Biophysical Research Communications 312 1196–1201.[CrossRef][ISI][Medline]
Leppä S, Saarto T, Vehmanen L, Blomqvist C & Elomaa I 2004 A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clinical Cancer Research 10 1057–1063.
Li G, Fridman R & Kim HRC 1999 Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Research 59 6267–6275.
Liu XW, Bernardo MM, Fridman R & Kim HRC 2003 Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signalling pathway. Journal of Biological Chemistry 278 40364–40372.
Look MP, Van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S et al. 2002 Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. Journal of the National Cancer Institute 94 116–128.
Luparello C, Avanzato G, Carella C & Pucci-Minafra I 1999 Tissue inhibitor of metalloproteinas (TIMP-1) and proliferative behaviour of clonal breast cancer cells. Breast Cancer Research and Treatment 54 235–244.[CrossRef][ISI][Medline]
Maskos K & Bode W 2003 Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Molecular Biotechnology 25 241–266.[CrossRef][ISI][Medline]
McCarthy K, Maguire T, McGreal G, McDermott E, O’Higgins N & Duffy MJ 1999 High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. International Journal of Cancer (Pred. Oncol.) 84 44–48.
Mirza AN, Mirza NQ, Vlastos G & Singletary E 2002 Prognostic factors in node-negative breast cancer. Annals of Surgery 235 10–26.[CrossRef][ISI][Medline]
Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJP, Benyon C & Iredale JP 2002 Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition. Journal of Biological Chemistry 277 11069–11076.
Murphy G, Houbrechts A, Cockett MI, Williamson RA, O’Shea M & Docherty AJP 1991 The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity. Biochemistry 30 8097–8102.
